GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

NCT00228839 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Graft vs Host Disease

Interventions

DRUG: Infliximab

Sponsor

Emory University